Tat-derived transport polypeptide
Abstract
Abstract This invention relates to delivery of biologically active cargo molecules such as polypeptides and nucleic acids into the cytoplasm and nuclei of cells in vitro and in vivo . Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise one or more portions of HIV tat protein and which are covalently attached to cargo molecules. The transport polypeptides of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region found in conventional tat proteins, transport polypeptides of this invention solve the problems of spurious trans-activation and disulfide aggregation. The reduced size of the transport polypeptides of this invention also minimizes interference with the biological activity of the cargo molecule.
Inventors
- 👤 James G. Barsoum
- 👤 Stephen E. Fawell
- 👤 R. Blake Pepinsky
Bibliographic Details
Claims Analysis
Total Claims: 4References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.